# Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study

> **NCT02316496** · PHASE2 · TERMINATED · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 2 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** cetuximab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT02316496
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-23
- **Primary completion:** 2016-01
- **Final completion:** 2017-01
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02316496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02316496, "Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02316496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*